Literature DB >> 1159331

Antimicrobial therapy of experimental intraabdominal sepsis.

W M Weinstein, A B Onderdonk, J G Bartlett, T J Louie, S L Gorbach.   

Abstract

Septic complications of colonic perforation involve miltiple bacteria derived from the intestinal flora. This type of mixed intraabdominal infection was produced experimentally by insertion of a standardized inoculum of rat colonic contents into the peritoneal cavity of male Wistar rats. The respective roles of coliforms and anerobic bacteria were then studied by use of selective antimicrobial therapy (with gentamicin and clindamycin). Untreated rats had a two-stage disease. Initally, there was an acute peritonitis associated with a 37% mortality rate; all animals that survived developed indolent intraabdominal abscesses. Treatment with gentamicin reduced the acute mortality rate to 4%, but 98% of the survivors had abscesses. Clindamycin acute mortalherapy was associated with a 35% mortality rate, but the incidence of intraabdominal abscess was only 5%. A combination of gentamicin and clindamycin yielded the salutary effects of each agent--7% mortality and 6% incidence of abscesses. These studies, in concert with bacteriological findings, suggest that coliforms caused early mortality while anaerobes were primarily responsible for the late complication of intraabdominal abscess formation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159331     DOI: 10.1093/infdis/132.3.282

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  39 in total

Review 1.  New developments and concepts in antimicrobial therapy for intra-abdominal infections.

Authors:  Z Younes; D A Johnson
Journal:  Curr Gastroenterol Rep       Date:  2000-08

Review 2.  In vivo antibiotic synergism: contribution of animal models.

Authors:  B Fantin; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

3.  Are enterococci playing a role in postoperative peritonitis in critically ill patients?

Authors:  P Seguin; C Brianchon; Y Launey; B Laviolle; N Nesseler; P-Y Donnio; Y Malledant
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-11-12       Impact factor: 3.267

Review 4.  Laparoscopic treatment of a sigmoid perforation after colonoscopy. Case report and review of literature.

Authors:  A Mehdi; J Closset; F Gay; J Deviere; J Houben; J Lambilliotte
Journal:  Surg Endosc       Date:  1996-06       Impact factor: 4.584

5.  Perioperative antibiotic therapy for penetrating injuries of the abdomen.

Authors:  L O Gentry; D V Feliciano; A S Lea; H D Short; K L Mattox; G L Jordan
Journal:  Ann Surg       Date:  1984-11       Impact factor: 12.969

6.  Therapeutic evaluation of difloxacin (A-56619) and A-56620 for experimentally induced Bacteroides fragilis-associated intra-abdominal abscess.

Authors:  H Thadepalli; S V Gollapudi; S K Chuah
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

Review 7.  Primary and secondary peritonitis: an update.

Authors:  M Laroche; G Harding
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-08       Impact factor: 3.267

8.  Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.

Authors:  A Pefanis; C Thauvin-Eliopoulos; J Holden; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Use of cefoxitin, new cephalosporin-like antibiotic, in the treatment of aerobic and anaerobic infections.

Authors:  S R Nair; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

10.  Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Authors:  J A Passarell; A K Meagher; K Liolios; B B Cirincione; S A Van Wart; T Babinchak; E J Ellis-Grosse; P G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2007-10-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.